Prophylactic granulopoiesis-stimulating factors for people with solid tumors undergoing cancer treatment.
Ma Mina M, Yang Minyan M, Wu Yanan Y, Li Wenjing W et al.
Many chemotherapy agents used in the treatment of solid tumors can induce myelosuppression, resulting in hematologic toxicities such as neutropenia and febrile neutropenia (FN), which are major causes of treatment-related morbidity and mortality. Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) are well-established stimulators of myelopoiesis and hematopoietic stem cell mobilization. Although previous reviews have suggested improved overall survival among individuals receiving intensified chemotherapy supported by primary G-CSF, it remains unclear whether prophylactic administration of G-CSF or GM-CSF itself improves overall survival, freedom from treatment failure (FFTF), or FN-associated complications when compared with placebo or no prophylaxis under the condition of identical treatment regimens. To assess the efficacy of prophylactic granulopoiesis-stimulating factors compared with placebo or no prophylaxis on survival outcomes and preventing adverse effects of cancer treatment in people with solid tumors. We searched CENTRAL, MEDLINE, and Embase and ongoing trials registers, together with reference checking, in June 2025. There were no restrictions on language or publication status. We included randomized controlled trials (RCTs) comparing primary granulopoiesis-stimulating factors with placebo or no prophylaxis in participants aged 18 years and older with solid tumors. Our outcomes were overall survival, FFTF, risk of infection, quality of life, all-cause mortality during chemotherapy, risk of bone pain, and duration of hospitalization. We used Cochrane's RoB 1 tool to assess risk of bias in the included studies. We synthesized results for each outcome using meta-analysis where possible. We assessed statistical heterogeneity between studies using a Chi2 test and I2 values. We used hazard ratios (HRs) with 95% confidence intervals (CIs) for time-to-event data and risk ratios (RRs) with 95% CIs for dichotomous outcomes. We used GRADE to assess the certainty of evidence for each outcome. We included 26 RCTs with a total of 5320 participants. We assessed two trials as having a high risk of bias, and the remaining studies as having a low or unclear risk of bias. Primary prophylaxis G-CSF or GM-CSF compared with control likely results in a reduction in risk of infection (RR 0.64, 95% CI 0.49 to 0.83; P = 0.001; 7 studies, 915 participants; moderate-certainty evidence), but may result in little to no difference in overall survival (HR 0.85, 95% CI 0.28 to 2.54; P = 0.59; 3 studies, 537 participants; low-certainty evidence) and FFTF (HR 0.89, 95% CI 0.63 to 1.25; P = 0.50; 1 study, 259 participants; low-certainty evidence). Primary prophylaxis G-CSF or GM-CSF compared with control likely results in little to no difference in all-cause mortality during chemotherapy (RR 0.92, 95% CI 0.53 to 1.60; P = 0.75; 11 studies, 3001 participants; moderate-certainty evidence). Regarding adverse events, primary prophylaxis G-CSF compared with control probably results in a large increase in risk of bone pain (RR 3.55, 95% CI 1.09 to 11.56; P = 0.04; 10 studies, 3152 participants; moderate-certainty evidence), a clinically important adverse outcome. One study reported that participants in the GM-CSF group had a significantly longer mean hospitalization duration (9.7 days versus 5.2 days, P < 0.01). Quality of life was not reported in any of the included studies. There is moderate-certainty evidence that primary prophylaxis G-CSF or GM-CSF likely reduces risk of infection versus control. In contrast, low- to moderate-certainty evidence suggests little to no improvement in overall survival and FFTF, and likely little to no difference between groups in all-cause mortality during chemotherapy. Regarding adverse events, moderate-certainty evidence shows a likely large increase in risk of bone pain. Data on the effects of prophylaxis G-CSF or GM-CSF compared to control on duration of hospitalization were inadequate to draw any conclusions, and no studies evaluated quality of life. We identified no new ongoing studies, and the number of recent publications is limited. Further research in this field is warranted. This Cochrane review was funded by the "Innovation Star" project of outstanding graduate students in Gansu Province (2023CXZX-142), China. Protocol was available via 10.1002/14651858.CD015656.